Why Alnylam Pharmaceuticals, Inc.’s (ALNY) Stock Is Down 24.37%
As of Thursday, July 30, Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 24.37%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. ALNY
$205.52
0.04
0.02%
July 31, 2026 4:00:00 PM
EST
Volume: 4,476,981
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Alnylam Pharmaceuticals, Inc.’s (ALNY) Stock Is Down 30.03%
As of Thursday, July 30, Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 30.03%, which has investors questioning if this is right time to buy.Omar Beirat
Is Alnylam Pharmaceuticals, Inc. (ALNY) Overvalued?
We dive into why Alnylam Pharmaceuticals, Inc. (ALNY) could be considered overvalued on 2026-07-17, based on AAII’s Value Score and Grade.Tudor Pop
Why Alnylam Pharmaceuticals, Inc.’s (ALNY) Stock Is Down 5.52%
As of Monday, July 13, Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Alnylam Pharmaceuticals, Inc.’s (ALNY) Stock Is Up 12.78%
As of Thursday, July 09, Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 12.78%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ALNY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $27,500.4 | $252.6 | 89% |
|
| Shares Out (Mil) | 138.3 | 52.3 | 69% |
|
| Institutional Ownership | 99.6% | 92.1% | 91% |
|
| Float (Mil) | 132.9 | 40.2 | 67% |
|
| Beta | 0.27 | 0.95 | 16% |
|
| Avg Daily Volume (000s) | 2,419 | 455 | 85% |
|
| Price Change (52-week) |
(39.5%) | 52.9% | 20% |
|
| Growth | ALNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 49.8% | 13.6% | 96% |
|
| Net Income (5yr) | 18.8% | (9.9%) | 71% |
|
| EPS (5yr) | 18.3% | 16.0% | 65 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 69.5% | (15.6%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 13 | 15 | |
| Current EPS | $2.197 | $9.041 | $13.114 | |
| Month Ago EPS | $2.435 | $9.421 | $13.574 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $2.384 | $9.269 | $13.961 | |
| Year/Year Chg | 81.6% | 288.0% | 610.0% | |
| Financials | ALNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,804 | $38 | 74% |
|
| Net Income (TTM) (Mil) | $775 | ($43) | 84% |
|
| EPS (TTM) | $5.845 | ($1.600) | 89% |
|
| Operating Cash Flow (TTM) (Mil) | $912 | ($31) | 80% |
|
| Net Cash Flow (TTM) (Mil) | $594 | $5 | 92% |
|
| Long-Term Debt (Q1) (Mil) | $2,683 | $5 | 78% |
|
| Enterprise Value (Q1) (Mil) | $37,947 | $180 | 90% |
|
| Valuation | ALNY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 20.29 | 2.56 | 96% |
|
| P/E | 36.6 | 19.0 | 75% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 2.0 | 0.9 | 67% |
|
| Ratios | ALNY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.7% | 63.8% | 89% |
|
| Net Margin | 16.1% | (67.3%) | 75% |
|
| ROA | 15.3% | (49.8%) | 94% |
|
| ROE | 96.6% | (55.5%) | 96% |
|
| Liabilities to Assets | 75.6% | 30.3% | 71% |
|
| F-Score | 7 | 3 | 84% |
|
Alnylam Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
